ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 8 of 42 for:    Recruiting, Not yet recruiting, Enrolling by invitation Studies | Astellas [Lead]

A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With Anemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02988973
Recruitment Status : Recruiting
First Posted : December 12, 2016
Last Update Posted : September 20, 2018
Sponsor:
Collaborator:
FibroGen
Information provided by (Responsible Party):
Astellas Pharma Inc

Brief Summary:
The objective of this study is to evaluate the efficacy and safety of ASP1517 when converted from recombinant human erythropoietin (rHuEPO) or darbepoetin alfa (DA), compared to DA in the treatment of anemia in non-dialysis chronic kidney disease patients. Another uncontrolled cohort will be included to evaluate the efficacy and safety of ASP1517 in patients converted from epoetin beta pegol (CERA). This study will also assess the safety/efficacy of long term treatment of ASP1517 (52 weeks).

Condition or disease Intervention/treatment Phase
Chronic Kidney Disease Drug: roxadustat Drug: DA Phase 3

Detailed Description:
This study consists of the following three cohorts. Cohort 1; subjects converted from rHuEPO or DA to ASP1517, Cohort 2; subjects converted from rHuEPO or DA to DA, Cohort 3; subjects converted from epoetin beta pegol (CERA) to ASP1517. In Cohort 1 and 3, ASP1517 will be administered orally for 52 weeks. In Cohort 2, DA will be administered subcutaneously for 24 weeks.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 325 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: ASP1517 Phase 3 Clinical Trial; A Multi-center, Randomized, Open-label, Active-comparator (Darbepoetin Alfa) Conversion Study of Intermittent Oral Dosing of ASP1517 in Non-dialysis Chronic Kidney Disease Patients With Anemia
Actual Study Start Date : January 12, 2017
Estimated Primary Completion Date : May 2019
Estimated Study Completion Date : November 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Subjects converting from rHuEPO or DA to ASP1517
ASP1517 will be administered for 52 weeks.
Drug: roxadustat
Oral administration
Other Name: ASP1517

Experimental: Subjects converting from rHuEPO or DA to DA
DA will be administered for 24 weeks.
Drug: DA
Subcutaneous administration

Experimental: Subjects converting from CERA to ASP1517
ASP1517 will be administered for 52 weeks.
Drug: roxadustat
Oral administration
Other Name: ASP1517




Primary Outcome Measures :
  1. Change from baseline in the average Hemoglobin (Hb) [ Time Frame: Baseline and Weeks 18 to 24 ]

Secondary Outcome Measures :
  1. Average Hb from Week 18 to Week 24 [ Time Frame: Up to Week 24 ]
  2. The number of subjects who achieve the target Hb level from Week 18 to Week 24 [ Time Frame: Up to Week 24 ]
  3. Proportion of Hb values within the target value in each post-dosing time point [ Time Frame: Up to Week 52 ]
  4. Change from baseline in Hb to each post-dosing time point [ Time Frame: Baseline and Up to Week 52 ]
  5. Proportion of time points that achieve the target Hb level from Weeks 18 to 24 [ Time Frame: Up to Week 24 ]
  6. Quality of life assessed by SF-36 [ Time Frame: Up to Week 52 ]
    SF-36: Medical Outcomes Study 36-Item Short-Form Health Survey

  7. Quality of life assessed by EQ-5D-5L [ Time Frame: Up to Week 52 ]
    EQ-5D: EuroQol 5 Dimension 5 Levels

  8. Quality of life assessed by WPAI:ANS [ Time Frame: Up to Week 52 ]
    WPAI:ANS: Work Productivity and Activity Impairment Questionnaire: Anaemic Symptoms

  9. Quality of life assessed by FACT-An [ Time Frame: Up to Week 52 ]
    FACT-An: Functional Assessment of Cancer Therapy-Anemia

  10. Average Hb from weeks 44 to 52 [ Time Frame: Up to Week 52 ]
  11. Change from baseline in the average Hb from weeks 44 to 52 [ Time Frame: Baseline and Up to Week 52 ]
  12. The number of subjects who achieve the target Hb level from Week 44 to Week 52 [ Time Frame: Up to Week 52 ]
  13. Proportion of time points that achieve the target Hb level from Weeks 44 to 52 [ Time Frame: Up to Week 52 ]
  14. Number of participants with abnormal Vital signs and/or adverse events related to treatment [ Time Frame: Up to Week 52 ]
  15. Safety assessed by body weight [ Time Frame: Up to Week 52 ]
  16. Safety assessed by incidence of adverse events [ Time Frame: Up to Week 52 ]
  17. Safety assessed by standard 12-lead electrocardiogram [ Time Frame: Up to Week 52 ]
  18. Safety assessed by ophthalmological examination: Fundoscopy [ Time Frame: Up to Week 24 ]
  19. Safety assessed by ophthalmological examination: optical coherence tomography [ Time Frame: Up to Week 24 ]
  20. Safety assessed by ophthalmological examination: visual acuity [ Time Frame: Up to Week 24 ]
  21. Number of participants with abnormal Laboratory values and/or adverse events related to treatment [ Time Frame: Up to Week 52 ]
  22. Plasma concentration of unchanged ASP1517 [ Time Frame: Up to Week 24 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects who were diagnosed with non-dialysis Chronic Kidney Disease and who are considered not to require renal replacement therapy during the study period
  • Subjects with renal anemia who have been receiving erythropoiesis stimulating agent (ESA) by subcutaneous injection and whose Hb values are considered stable.
  • Mean of the subject's two most recent Hb values before randomization during the Screening Period must be ≥10.0 g/dL and ≤12.0 g/dL
  • Either transferrin saturation ≥ 20% or serum ferritin ≥ 100 ng/mL
  • Female subject must either:

Be of non-childbearing potential:

  • post-menopausal, or
  • documented surgically sterile Or, if of childbearing potential,
  • Agree not to try to become pregnant during the study and for 28 days after the final study drug administration
  • And have a negative urine pregnancy test at pre-screening
  • And, if heterosexually active, agree to consistently use two forms of highly effective birth control* (at least one of which must be a barrier method) starting at pre-screening and throughout the study period and continued for 28 days after the final study drug administration.

    • Female subject must agree not to breastfeed starting at pre-screening and throughout the study period, and continued for 28 days after the final study drug administration.
    • Female subject must not donate ova starting at pre-screening and throughout the study period, and continued for 28 days after the final study drug administration.
    • Male subject and their female spouse/partners who are of childbearing potential must be using two forms of highly effective birth control (at least one of which must be a barrier method) starting at pre-screening and continue throughout the study period, and for 12 weeks after the final study drug administration
    • Male subject must not donate sperm starting at pre-screening and throughout the study period and, for 12 weeks after the final study drug administration

Exclusion Criteria:

  • Concurrent retinal neovascular lesion untreated or macular edema untreated, and patients with any condition that significantly compromises the ability to visualize the retina
  • Concurrent autoimmune disease with inflammation that could impact erythropoiesis
  • History of gastric/intestinal resection considered influential on the absorption of drugs in the gastrointestinal tract (excluding resection of gastric or colon polyps) or concurrent gastro-paresis
  • Uncontrolled hypertension
  • Concurrent congestive heart failure (NYHA Class III or higher)
  • History of hospitalization for treatment of stroke, myocardial infarction, or pulmonary embolism within 12 weeks before the pre-screening assessment
  • Positive for hepatitis B surface antigen (HBsAg) or anti-hepatitis C virus (HCV) antibody at the pre-screening assessment, or positive for human immunodeficiency virus (HIV) in a past test
  • Concurrent other form of anemia than renal anemia
  • History of pure red cell aplasia
  • Having received treatment with protein anabolic hormone, testosterone enanthate, or mepitiostane within 6 weeks before the pre-screening assessment
  • Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), or total bilirubin that is greater than the criteria, or previous or concurrent another serious liver disease at pre-screening assessment
  • Previous or current malignant tumor (no recurrence for at least 5 years is eligible.)
  • Having undergone red blood transfusion and/or a surgical procedure consider to promote anemia and/or ophthalmological surgery within 4 weeks before the pre-screening assessment
  • Having undergone a kidney transplantation
  • History of serious drug allergy including anaphylactic shock
  • Having a previous history of treatment with ASP1517 or participation in this study
  • Participation in another clinical study or post-marketing clinical study (including that of a medical device) within 12 weeks before informed consent acquisition

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02988973


Contacts
Contact: Astellas Pharma Inc. +81-3-3244-0512 Astellas.registration@astellas.com

  Show 71 Study Locations
Sponsors and Collaborators
Astellas Pharma Inc
FibroGen
Investigators
Study Director: Medical Director Astellas Pharma Inc

Responsible Party: Astellas Pharma Inc
ClinicalTrials.gov Identifier: NCT02988973     History of Changes
Other Study ID Numbers: 1517-CL-0310
First Posted: December 12, 2016    Key Record Dates
Last Update Posted: September 20, 2018
Last Verified: September 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Astellas Pharma Inc:
Roxadustat
Anemia
Non-dialysis chronic kidney disease
ASP1517

Additional relevant MeSH terms:
Anemia
Kidney Diseases
Renal Insufficiency, Chronic
Hematologic Diseases
Urologic Diseases
Renal Insufficiency